Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB9 | P28065 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 12/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24666462 | 1.00 | PSMB9 (0.44) | PSMB9CFDTACR1S1PR2S1PR3 | |
| SCHEMBL29230715 | 0.90 | PSMB9 (0.42) | PSMB9CFD | |
| SCHEMBL24666492 | 0.90 | PSMB9 (0.42) | PSMB9CFD | |
| SCHEMBL29230716 | 0.90 | PSMB9 (0.48) | PSMB9CFDTACR1MMP9 | |
| SCHEMBL26817652 | 0.90 | PSMB9 (0.48) | PSMB9CFDTACR1MMP9 | |
| SCHEMBL24666501 | 0.89 | PSMB9 (0.41) | PSMB9CFDDRD2 | |
| SCHEMBL29820248 | 0.89 | PSMB9 (0.41) | PSMB9CFDDRD2 | |
| SCHEMBL24664502 | 0.88 | PSMB9 (0.43) | PSMB9CFDTACR1S1PR2S1PR3 | |
| SCHEMBL29820286 | 0.88 | PSMB9 (0.43) | PSMB9CFDTACR1S1PR2S1PR3 | |
| SCHEMBL24666605 | 0.88 | PSMB9 (0.43) | PSMB9CFDTACR1S1PR2S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |